{'fraction_non_alphanumeric': 0.013642564802182811, 'fraction_numerical': 0.004092769440654843, 'mean_word_length': 5.43859649122807, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anticardiolipin antibodies are not associated with rheumatic heart disease

The aim of this study was to examine the prevalence of anticardiolipin antibodies in rheumatic valve heart disease. Serum samples of 31 consecutive patients with rheumaticheart disease and documented valve involvement, as well assix patients with acute rheumatic fever were tested for IgGanticardiolipin antibodies by a validated ELISA. No anticardiolipin antibodies were found when a cut-off point set at mean 5 s.d. was applied. We can conclude that anticardiolipin antibodies are notpresent in rheumatic heart disease patients and, as suggested by several observations, these antibodies do not appear to have a pathogenic role in this particular disease.